BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced its first ...
A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.
The US FDA is set to introduce a faster approval process for personalized gene editing therapies, aiming to accelerate investment and development of treatments for rare diseases, highlighted by the ...
In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback